Salvage Therapy with High Dose Bicalutamide (Casodex) In Non-metastatic Castration-Resistant Prostate Cancer – It Controls PSA and Disease Progression

Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate cancer (nmHRPC) as well as its impact on the duration of metastasis-free survival. They concluded that high dose bicalutamide is capable of inducing a PSA response and in extending progression free survival even if the man is hormone resistant.